

CLINICALLY SIGNIFICANT BENEFIT (PFS \geq 23 WEEKS and ON STUDY FOR \geq 23 weeks)

Total patients	14/40 (35%)
Ovarian Group	5/20(25%)
Low-grade serous	3/3 (100%)*
High-grade serous	2/17 (12%)
Endometrial Group	9/20 (45%)
Grade 1-2	7/11 (64%)
Grade 3	2/9 (22%)

*These patients are still on rx for 28+ months, 24+ months, and 19+ months.